Premium
COX‐2 inhibitors show no preventive effect in the development of skin cancer
Author(s) -
Yen Hsuan,
Yen Hsi,
Drucker Aaron M.,
Han Jiali,
Li WenQing,
Li Tricia,
Qureshi Abrar,
Cho Eunyoung
Publication year - 2022
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/ddg.14649
Subject(s) - hazard ratio , medicine , proportional hazards model , skin cancer , cancer , confidence interval , prospective cohort study , basal cell carcinoma , melanoma , oncology , relative risk , basal cell , cancer research
Summary Background Some clinical trials found that cyclooxygenase‐2 (COX‐2) inhibitor use lowered the risk of skin cancer in high‐risk groups. Patients and Methods To determine whether COX‐2 inhibitor use is associated with lower risk of basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and melanoma, we analyzed COX‐2 inhibitor use and risk of skin cancer based on three prospective cohort studies, the Nurses’ Health Study (NHS), NHS II, and the Health Professionals Follow‐up Study, including 153,882 participants. Multivariable hazard ratios (HRs) and 95 % confidence intervals (CIs) for the association of COX‐2 inhibitor use with risk of BCC, cSCC, and melanoma were estimated using Cox proportional hazards models. We pooled the results using a fixed effects model. Results 16,142 BCC, 1,973 cSCC, and 631 melanoma cases were documented. Ever vs. never use of COX‐2 inhibitor was associated with a modestly increased risk of BCC (multivariable HR 1.09, 95 % CI 1.05–1.14). The hazard ratio was similar for cSCC (multivariable HR 1.12, 95 % CI 1.00–1.27) and melanoma (multivariable HR 1.10, 95 % CI 0.89–1.38), but was not statistically significant. Conclusions Ever use of COX‐2 inhibitor was not associated with a decreased skin cancer risk but was instead associated with a modest, increased risk of BCC.